PROLIGHT DIAGNOSTICS AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.145 SEK | +23.93% |
|
+23.93% | -51.83% |
| May. 17 | Prolight Diagnostics Gets SEK17 Million Grant to Advance Product Development | MT |
| May. 17 | Prolight Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Calendar
2024-08-27
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -51.83% | 6.88M | |
| -38.56% | 8.39B | |
| +0.18% | 3.32B | |
| +9.29% | 2.48B | |
| -18.21% | 2.06B | |
| -24.57% | 1.59B | |
| +32.37% | 1.15B | |
| -7.64% | 704M | |
| +8.42% | 678M | |
| -29.59% | 508M |
- Stock Market
- Equities
- PRLD Stock
- News Prolight Diagnostics AB
- Prolight Diagnostics Gets SEK17 Million Grant to Advance Product Development
